Short answer
ABEONA THERAPEUTICS INC. (ABEO) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Section 2.02 text contains only legal safe-harbor language.
ABEONA THERAPEUTICS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Section 2.02 text contains only legal safe-harbor language
- No fiscal-year 2026 financial results or operating metrics disclosed
- Investors must review the referenced exhibit for substantive earnings information
Item EX-99.1 · Exhibit EX-99.1
- Q2 ZEVASKYN revenue $11.4M, up 31% quarter-over-quarter from $8.7M, signaling early commercial traction
- Five Q2 treatments and 12 since launch, but two treatments generated no revenue due to manufacturing yield or lot-release issues
- QTC network expanded to seven sites, with CHOP, UTMB and Cincinnati Children’s advancing patient access
- CMS NTAP status effective October 1, 2026, supporting hospital reimbursement for Medicare patients representing approximately 10% of RDEB patients
- Cash $146.8M versus $191.4M at December 31, 2025, alongside Q2 net loss $(20.2)M and continued funding needs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ABEONA THERAPEUTICS INC. 8-K filings
Get the next ABEO 8-K as it lands
Follow ABEO for push alerts, or ask the research agent what this filing means.